Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
SURGERY	O
Allergies:	O
Vicodin	O
Attending:	O
___.	O
Chief	O
Complaint:	O
rectal	O
pain	O
and	O
constipation	B-Constipation
x	O
1.5	O
weeks	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Ileostomy	O
take-down,	O
Excision	O
RLE	O
mass	O
History	O
of	O
Present	O
Illness:	O
Mrs.	O
___	O
is	O
a	O
___	O
year	O
old	O
woman	O
with	O
PMHx	O
notable	O
for	O
rectal	O
CA	O
s/p	O
LAR	O
w/	O
diverting	O
loop	O
ileostomy	O
on	O
___	O
with	O
post-op	O
course	O
c/b	O
anastomotic	O
leak	O
treated	O
with	O
___	O
drainage	O
and	O
s/p	O
chemotherapy	O
since	O
___	O
presented	O
on	O
___	O
with	O
rectal	O
pain	O
and	O
constipation	B-Constipation
x	O
1.5	O
weeks.	O
In	O
brief,	O
Mrs.	O
___	O
stated	O
that	O
she	O
had	O
been	O
in	O
usual	O
state	O
of	O
health,	O
tolerating	O
a	O
regular	O
diet,	O
and	O
having	O
normal	O
ileostomy	O
output	O
until	O
~	O
___.	O
She	O
underwent	O
scheduled	O
colonoscopy	O
on	O
___	O
as	O
part	O
of	O
preoperative	O
evaluation	O
prior	O
to	O
ileostomy	O
takedown	O
on	O
___.	O
Pt	O
states	O
that	O
she	O
had	O
one	O
enema	O
at	O
that	O
time,	O
was	O
scoped	O
from	O
her	O
rectum	O
and	O
from	O
ostomy.	O
Colonoscopy	O
was	O
not	O
successful	O
secondary	O
to	O
significant	O
stool	O
throughout	O
colon.	O
She	O
subsequently	O
underwent	O
repeat	O
colonoscopy	O
on	O
___,	O
with	O
prep	O
consisting	O
of	O
2	O
enemas,	O
which	O
reportedly	O
demonstrated	O
persistent	O
impacted	O
stool	O
approximately	O
25	O
cm	O
from	O
rectal	O
verge	O
with	O
significant	O
erythema	O
noted	O
in	O
rectum.	O
Since	O
undergoing	O
the	O
aforementioned	O
colonoscopies,	O
Mrs.	O
___	O
had	O
not	O
had	O
any	O
difficulties	O
with	O
diet,	O
or	O
had	O
any	O
episodes	O
of	O
nausea,	O
vomiting,	O
or	O
decreased	O
output	O
per	O
ostomy.	O
She	O
did	O
endorse,	O
however,	O
persistent	O
rectal	O
pain	O
in	O
the	O
setting	O
of	O
new-onset	O
oozing	O
from	O
her	O
rectum	O
(dark	O
brown	O
fluid)	O
and	O
change	O
in	O
ostomy	O
output	O
(thinner,	O
more	O
green-brown	O
than	O
prior).	O
Mrs.	O
___	O
denied	O
fevers,	O
chills,	O
diffuse	O
abdominal	O
pain,	O
blood	B-Lower_gastrointestinal_haemorrhage
per	B-Lower_gastrointestinal_haemorrhage
rectum,	B-Lower_gastrointestinal_haemorrhage
or	O
hematemesis.	B-Upper_gastrointestinal_haemorrhage
Past	O
Medical	O
History:	O
PMHx:	O
Rectal	O
CA,	O
COPD,	O
cardiomyopathy	O
EF	O
25%	O
___,	O
LBBB,	O
CAD,	O
HLD,	O
small	O
___	O
venous	O
thromboses	O
within	O
last	O
___	O
months	O
(on	O
AC	O
since;	O
transitioned	O
from	O
coumadin	O
to	O
lovenox	O
prior	O
to	O
colonoscopies)	O
PSHx:	O
TAH,	O
tubal	O
ligation,	O
varicose	O
veins,	O
LAR	O
w/	O
diverting	O
loop	O
ileostomy	O
c/b	O
anastomotic	O
leak	O
Social	O
History:	O
___	O
Family	O
History:	O
No	O
known	O
GI	O
diseases	O
Physical	O
Exam:	O
97.8F	O
60	O
123/59	O
18	O
98%RA	O
Gen	O
-	O
NAD,	O
resting	O
comfortably	O
in	O
bed	O
HEENT	O
-	O
MMM,	O
PERRL,	O
wears	O
hearing	B-Hearing_impairment
aid	B-Hearing_impairment
CV	O
-	O
RRR,	O
nml	O
S1/S2,	O
no	O
M/R/G	O
Resp	O
-	O
CTAB,	O
no	O
W/R/R	O
Abd	O
-	O
S,	O
NT/ND,	O
+BS,	O
no	O
rebound/guarding;	O
small	O
non-tender	O
area	O
of	O
ecchymotic	O
prominance,	O
somewhat	O
indurated,	O
approx	O
10	O
cm	O
x	O
6	O
cm,	O
located	O
underneath	O
abd	O
incision;	O
some	O
other	O
areas	O
of	O
soft	O
ecchymosis,	O
likely	O
secondary	O
to	O
SC	O
heparin	O
shots	O
Wound	O
-	O
abdominal	O
incisions	O
C/D/I,	O
dressings	O
in	O
place	O
Ext	O
-	O
WWP,	O
no	O
C/C/E	O
Neuro	O
-	O
AAOx3,	B-Delirium
CN2-12	O
grossly	O
intact	O
Pertinent	O
Results:	O
___	O
12:45PM	O
BLOOD	O
WBC-3.4*	O
RBC-3.52*	O
Hgb-11.7*	O
Hct-34.9*	O
MCV-99*#	O
MCH-33.1*#	O
MCHC-33.4#	O
RDW-15.2	O
Plt	O
Ct-96*#	O
___	O
12:45PM	O
BLOOD	O
Neuts-67.7	O
___	O
Monos-10.4	O
Eos-1.0	O
Baso-0.3	O
___	O
06:55AM	O
BLOOD	O
WBC-16.9*#	O
RBC-3.66*	O
Hgb-11.9*	O
Hct-37.1	O
MCV-102*	O
MCH-32.6*	O
MCHC-32.1	O
RDW-15.0	O
Plt	O
___	O
___	O
07:00AM	O
BLOOD	O
WBC-21.1*	O
RBC-3.80*	O
Hgb-12.3	O
Hct-38.1	O
MCV-100*	O
MCH-32.5*	O
MCHC-32.4	O
RDW-15.1	O
Plt	O
___	O
___	O
07:00AM	O
BLOOD	O
Neuts-92.7*	O
Lymphs-5.2*	O
Monos-1.6*	O
Eos-0.4	O
Baso-0.1	O
___	O
09:10AM	O
BLOOD	O
WBC-8.4	O
RBC-3.18*	O
Hgb-10.5*	O
Hct-32.0*	O
MCV-100*	O
MCH-32.8*	O
MCHC-32.7	O
RDW-15.0	O
Plt	O
___	O
___	O
10:45AM	O
BLOOD	O
WBC-3.4*#	O
RBC-3.06*	O
Hgb-10.2*	O
Hct-30.4*	O
MCV-100*	O
MCH-33.3*	O
MCHC-33.5	O
RDW-14.3	O
Plt	O
___	O
___	O
12:45PM	O
BLOOD	O
Plt	O
Smr-LOW	O
Plt	O
Ct-96*#	O
___	O
01:32PM	O
BLOOD	O
___	O
PTT-35.1	O
___	O
___	O
06:00AM	O
BLOOD	O
___	O
PTT-36.9*	O
___	O
___	O
06:00AM	O
BLOOD	O
Plt	O
___	O
___	O
09:10AM	O
BLOOD	O
___	O
PTT-35.8	O
___	O
___	O
09:10AM	O
BLOOD	O
Plt	O
___	O
___	O
10:45AM	O
BLOOD	O
Plt	O
___	O
___	O
09:05AM	O
BLOOD	O
___	O
___	O
07:00AM	O
BLOOD	O
___	O
___	O
___	O
07:35AM	O
BLOOD	O
___	O
___	O
___	O
12:45PM	O
BLOOD	O
Glucose-103*	O
UreaN-8	O
Creat-0.6	O
Na-137	O
K-4.0	O
Cl-103	O
HCO3-24	O
AnGap-14	O
___	O
07:00AM	O
BLOOD	O
Glucose-96	O
UreaN-5*	O
Creat-0.5	O
Na-139	O
K-3.8	O
Cl-105	O
HCO3-27	O
AnGap-11	O
___	O
06:00AM	O
BLOOD	O
Glucose-96	O
UreaN-8	O
Creat-0.5	O
Na-147*	O
K-4.4	O
Cl-111*	O
HCO3-27	O
AnGap-13	O
___	O
06:00AM	O
BLOOD	O
Glucose-77	O
UreaN-8	O
Creat-0.5	O
Na-139	O
K-3.8	O
Cl-104	O
HCO3-23	O
AnGap-16	O
___	O
09:05AM	O
BLOOD	O
Glucose-120*	O
UreaN-7	O
Creat-0.5	O
Na-140	O
K-4.3	O
Cl-105	O
HCO3-28	O
AnGap-11	O
___	O
12:45PM	O
BLOOD	O
ALT-23	O
AST-44*	O
AlkPhos-149*	O
TotBili-0.7	O
___	O
12:45PM	O
BLOOD	O
Albumin-3.5	O
___	O
05:30AM	O
BLOOD	O
Calcium-8.5	O
Phos-3.7	O
___	O
05:55AM	O
BLOOD	O
Calcium-8.7	O
Phos-4.7*	O
Mg-1.7	O
___	O
09:10AM	O
BLOOD	O
Calcium-8.3*	O
Phos-3.3	O
Mg-1.9	O
___	O
09:05AM	O
BLOOD	O
Calcium-9.1	O
Phos-3.8	O
Mg-1.9	O
___	O
12:57PM	O
BLOOD	O
Lactate-1.9	O
___	O
8:55PM	O
URINE,	O
Catheter.	O
*FINAL	O
REPORT	O
___:	O
ENTEROCOCCUS	O
SP.	O
>100,000	O
ORGANISMS/ML.	O
___	O
6:15AM	O
BLOOD	O
CULTURE	O
**FINAL	O
REPORT	O
___:	O
NO	O
GROWTH.	O
___	O
XRay	O
Abdomen:	O
Moderate	O
amount	O
of	O
stool	O
in	O
the	O
colon.	O
Non-obstructive	O
bowel	O
gas	O
pattern.	O
___	O
XRay	O
Abdomen:	O
There	O
is	O
fecal	O
material	O
in	O
the	O
transverse	O
left	O
colon	O
and	O
sigmoid	O
colon.	O
There	O
is	O
air	O
in	O
the	O
rectum.	O
There	O
is	O
no	O
evidence	O
of	O
obstruction.	O
There	O
are	O
moderate-to-severe	O
degenerative	O
changes	O
in	O
the	O
lumbar	O
spine.	O
There	O
is	O
mild	O
left	O
scoliosis.	O
___	O
Pathology	O
Examination	O
of	O
Ileostomy	O
specimen:	O
Two	O
fragments	O
of	O
bowel	O
measuring	O
5.6	O
x	O
0.7	O
x	O
0.9	O
cm	O
and	O
2	O
x	O
0.6	O
x	O
0.5	O
cm	O
respectively.	O
There	O
is	O
an	O
external	O
cauterized	O
surface	O
and	O
internal	O
mucosa	O
that	O
appears	O
unremarkable.	O
Skin	O
and	O
subcutaneous	O
tissue,	O
and	O
small	O
intestinal	O
segment	O
with	O
changes	O
of	O
ileostomy	O
site.	O
___	O
Pathology	O
Examination	O
of	O
RLE	O
Soft	O
Tissue	O
Specimen:	O
The	O
first	O
piece	O
measures	O
1.9	O
x	O
1.5	O
x	O
0.6	O
cm	O
and	O
the	O
second	O
measures	O
1.8	O
x	O
1.1	O
x	O
0.5	O
cm.	O
Nodular	O
fat	O
necrosis,	O
suggestive	O
of	O
piezogenic	O
papule.	O
___	O
Immunophenotyping	O
-	O
RLE	O
mass:	O
The	O
following	O
tests	O
(antibodies)	O
were	O
performed:	O
___,	O
FMC-7,	O
Kappa,	O
Lambda,	O
and	O
CD	O
antigens	O
3,	O
5,	O
10,	O
19,	O
20,	O
23.	O
Non-specific	O
T	O
cell	O
dominant	O
lymphoid	O
profile;	O
diagnostic	O
immunophenotypic	O
features	O
of	O
involvement	O
by	O
leukemia/lymphoma	O
are	O
not	O
seen	O
in	O
specimen.	O
Correlation	O
with	O
clinical	O
findings	O
is	O
recommended.	O
Flow	O
cytometry	O
immunophenotyping	O
may	O
not	O
detect	O
all	O
lymphomas	O
due	O
to	O
topography,	O
sampling	O
or	O
artifacts	O
of	O
sample	O
preparation.	O
Brief	O
Hospital	O
Course:	O
Mrs.	O
___	O
presented	O
to	O
___	O
ED	O
on	O
___	O
for	O
fecal	B-Constipation
impaction.	B-Constipation
In	O
an	O
attempt	O
to	O
disimpact	O
her	O
bowels,	O
she	O
underwent	O
several	O
rounds	O
of	O
enemas,	O
including	O
Golytely	O
and	O
soap	O
suds.	O
She	O
ultimately	O
began	O
to	O
have	O
some	O
fecal	O
output	O
through	O
her	O
ostomy	O
and	O
minimal	O
hard	O
stools	O
via	O
her	O
rectum	O
and	O
was	O
deemed	O
fit	O
for	O
reversal	O
of	O
her	O
ostomy.	O
However,	O
surgery	O
was	O
delayed	O
due	O
to	O
worsening	O
leukocytopenia	O
of	O
unclear	O
etiology;	O
she	O
was	O
administered	O
Neupogen	O
on	O
hospital	O
day	O
8	O
with	O
subsequent	O
improvement	O
of	O
her	O
white	O
count.	O
Furthermore,	O
on	O
hospital	O
day	O
2,	O
she	O
was	O
noted	O
to	O
have	O
urinary	O
retention,	O
with	O
bladder	O
scan	O
revealing	O
>1L	O
fluid.	O
Urology	O
was	O
consulted	O
and	O
believed	O
her	O
urinary	O
symptoms	O
to	O
be	O
due	O
to	O
increased	O
pressure	O
from	O
fecal	O
impaction;	O
they	O
would	O
like	O
her	O
to	O
follow	O
up	O
with	O
the	O
urology	O
clinica	O
as	O
an	O
outpatient	O
to	O
review	O
this	O
further.	O
On	O
hospital	O
day	O
3,	O
she	O
was	O
noted	O
to	O
have	O
a	O
enterococcalurinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection,	B-Urinary_tract_infection
likely	O
secondary	O
to	O
the	O
previously	O
described	O
retention	O
and	O
catheterization.	O
She	O
was	O
treated	O
with	O
Macrobid,	O
with	O
resolution	O
of	O
her	O
symptoms.	O
Urinary	O
output	O
remained	O
normal	O
throughout	O
the	O
remainder	O
of	O
her	O
hospital	O
stay.	O
On	O
hospital	O
day	O
10	O
(___),	O
Mrs.	O
___	O
was	O
determined	O
to	O
be	O
stable	O
for	O
surgery,	O
with	O
no	O
evidence	O
of	O
colonic	B-Constipation
obstruction	O
or	O
of	O
impaction,	B-Constipation
with	O
an	O
improved	O
white	O
count	O
and	O
with	O
resolution	O
of	O
her	O
urinary	O
symptoms.	O
She	O
underwent	O
successful	O
reversal	O
of	O
her	O
ostomy.	O
Prior	O
to	O
the	O
operation,	O
some	O
leg	O
lesions	O
had	O
also	O
been	O
noted	O
and	O
were	O
worrisome	O
for	O
a	O
malignant	O
process.	O
On	O
recommendation	O
from	O
the	O
patient's	O
oncologist,	O
these	O
were	O
also	O
biopsied	O
without	O
complication	O
at	O
the	O
time	O
of	O
her	O
ileostomy.	O
Immunophenotyping	O
was	O
negative	O
for	O
lymphoma	O
or	O
leukemia	O
and	O
the	O
lesions	O
were	O
thought	O
to	O
be	O
likely	O
piezogenic	O
papules.	O
Ms.	O
___	O
tolerated	O
the	O
procedure	O
without	O
complications	O
and	O
recovered	O
uneventfully	O
in	O
the	O
PACU	O
before	O
being	O
transferred	O
to	O
the	O
floor	O
in	O
stable	O
condition.	O
(Please	O
see	O
the	O
associated	O
operative	O
report	O
for	O
specific	O
procedural	O
details.)	O
Post-operatively	O
her	O
pain	O
was	O
controlled	O
with	O
a	O
PCA/IV	O
pain	O
medication	O
with	O
a	O
transition	O
to	O
PO	O
pain	O
meds	O
once	O
tolerating	O
POs.	O
Her	O
diet	O
was	O
advanced	O
slowly	O
and	O
without	O
difficulty.	O
She	O
regained	O
normal	O
bowel	O
function	O
and	O
continued	O
to	O
have	O
good	O
urine	O
output.	O
Her	O
white	O
blood	O
count	O
again	O
began	O
to	O
decrease,	O
but	O
this	O
was	O
expected	O
after	O
Neupogen	O
treatment.	O
She	O
remained	O
hemodynamically	O
stable	O
for	O
her	O
entire	O
hospital	O
course.	O
She	O
received	O
___	O
antibiotics	O
as	O
well	O
as	O
coumadin	O
and	O
lovenox	O
for	O
DVT	O
prophylaxis.	O
Her	O
incision	O
was	O
clean,	O
dry,	O
and	O
intact	O
without	O
evidence	O
of	O
erythema	O
or	O
drainage.	O
She	O
was	O
discharged	O
in	O
stable	O
condition	O
with	O
written	O
instructions	O
concerning	O
precautionary	O
instructions	O
and	O
the	O
appropriate	O
follow-up	O
care,	O
including	O
prescriptions	O
for	O
lovenox	O
and	O
coumadin	O
and	O
instructions	O
to	O
have	O
her	O
INR	O
checked	O
on	O
___	O
by	O
the	O
person	O
(Dr.	O
___	O
who	O
normally	O
manages	O
her	O
coumadin.	O
All	O
questions	O
were	O
answered	O
prior	O
to	O
discharge,	O
and	O
she	O
expressed	O
readiness	O
for	O
discharge.	O
Medications	O
on	O
Admission:	O
Symbicort	O
80-4.5	O
1	O
puff'',	O
Spiriva	O
18mcg',	O
Paroxetine	O
30',	O
Docusate	O
100'',	O
Lorazepam	O
1''''PRN,	O
Prednisolone	O
cetate	O
Ophtalmic	O
1%	O
1gtt	O
each	O
eye',	O
Chantix,	O
Albuterol	O
0.083/2.5/3ml	O
''''''PRN,	O
Proair	O
HFA	O
90mcg	O
2Puffs''''PRN,	O
FeSulfate	O
65',	O
Coreg	O
6.25'',	O
Lisinopril	O
2.5',	O
Ambien	O
10'PRN	O
Discharge	O
Medications:	O
1.	O
Gabapentin	O
400	O
mg	O
PO	O
HS	O
2.	O
PrednisoLONE	O
Acetate	O
1%	O
Ophth.	O
Susp.	O
1	O
DROP	O
BOTH	O
EYES	O
DAILY	O
3.	O
Sertraline	O
50	O
mg	O
PO	O
DAILY	O
4.	O
Zolpidem	O
Tartrate	O
10	O
mg	O
PO	O
HS:PRN	O
insomnia	O
5.	O
Tiotropium	O
Bromide	O
1	O
CAP	O
IH	O
DAILY	O
6.	O
Fluticasone-Salmeterol	O
Diskus	O
(100/50)	O
1	O
INH	O
IH	O
BID	O
7.	O
Albuterol	O
Inhaler	O
1	O
PUFF	O
IH	O
Q6H:PRN	O
wheezing	O
8.	O
Bisacodyl	O
10	O
mg	O
PR	O
HS:PRN	O
bm	O
RX	O
*bisacodyl	O
10	O
mg	O
1	O
Suppository(s)	O
rectally	O
before	O
sleep	O
Disp	O
#*20	O
Suppository	O
Refills:*0	O
9.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
RX	O
*docusate	O
sodium	O
100	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
10.	O
Enoxaparin	O
Sodium	O
120	O
mg	O
SC	O
DAILY	O
RX	O
*enoxaparin	O
120	O
mg/0.8	O
mL	O
Inject	O
in	O
thigh	O
once	O
a	O
day	O
Disp	O
#*10	O
Syringe	O
Refills:*0	O
11.	O
OxycoDONE	O
(Immediate	O
Release)	O
___	O
mg	O
PO	O
Q4H:PRN	O
pain	O
RX	O
*oxycodone	O
5	O
mg	O
___	O
tablet(s)	O
by	O
mouth	O
every	O
four	O
(4)	O
hours	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
12.	O
Psyllium	O
Wafer	O
1	O
WAF	O
PO	O
TID	O
If	O
you	O
experience	O
loose	O
stool	O
or	O
diarrhea,	O
please	O
call	O
Dr.	O
___	O
instructions	O
on	O
taking	O
this	O
medication	O
RX	O
*psyllium	O
[Metamucil]	O
1	O
wafer(s)	O
by	O
mouth	O
per	O
Dr.	O
___	O
Disp	O
#*1	O
Box	O
Refills:*0	O
13.	O
Warfarin	O
5	O
mg	O
PO	O
DAILY	O
RX	O
*warfarin	O
5	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
DAILY	O
Disp	O
#*20	O
Tablet	O
Refills:*0	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	O
Facility:	O
___	O
___	O
Diagnosis:	O
Fecal	B-Constipation
impaction	B-Constipation
Rectal	O
Cancer	O
S/p	O
Ileostomy	O
Subcutaneous	O
leg	O
mass	O
Neutropenia	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
the	O
general	O
surgery	O
service	O
atfer	O
having	O
rectal	O
pain	O
and	O
constipation	B-Constipation
x	O
1.5	O
weeks;	O
you	O
had	O
surgery	O
to	O
reverse	O
your	O
ileostomy.	O
Please	O
resume	O
all	O
regular	O
home	O
medications,	O
unless	O
specifically	O
advised	O
not	O
to	O
take	O
a	O
particular	O
medication.	O
Please	O
take	O
any	O
new	O
medications	O
as	O
prescribed.	O
Please	O
take	O
the	O
prescribed	O
analgesic	O
medications	O
as	O
needed.	O
You	O
may	O
not	O
drive	O
or	O
heavy	O
machinery	O
while	O
taking	O
narcotic	O
analgesic	O
medications.	O
You	O
may	O
also	O
take	O
acetaminophen	O
(Tylenol)	O
as	O
directed,	O
but	O
do	O
not	O
exceed	O
3000	O
mg	O
in	O
one	O
day.	O
Please	O
get	O
plenty	O
of	O
rest,	O
continue	O
to	O
walk	O
several	O
times	O
per	O
day,	O
and	O
drink	O
adequate	O
amounts	O
of	O
fluids.	O
Avoid	O
strenuous	O
physical	O
activity	O
and	O
refrain	O
from	O
heavy	O
lifting	O
greater	O
than	O
10	O
lbs.,	O
until	O
you	O
follow-up	O
with	O
your	O
surgeon,	O
who	O
will	O
instruct	O
you	O
further	O
regarding	O
activity	O
restrictions.	O
Please	O
also	O
follow-up	O
with	O
your	O
primary	O
care	O
physician.	O
Incision	O
Care:	O
*Please	O
call	O
your	O
surgeon	O
or	O
go	O
to	O
the	O
emergency	O
department	O
if	O
you	O
have	O
increased	O
pain,	O
swelling,	O
redness,	O
or	O
drainage	O
from	O
the	O
incision	O
site.	O
*Avoid	O
swimming	O
and	O
baths	O
until	O
cleared	O
by	O
your	O
surgeon.	O
*You	O
may	O
shower	O
and	O
wash	O
incisions	O
with	O
a	O
mild	O
soap	O
and	O
warm	O
water.	O
Gently	O
pat	O
the	O
area	O
dry.	O
*If	O
you	O
have	O
staples,	O
they	O
will	O
be	O
removed	O
at	O
your	O
follow-up	O
appointment.	O
*If	O
you	O
have	O
steri-strips,	O
they	O
will	O
fall	O
off	O
on	O
their	O
own.	O
Please	O
remove	O
any	O
remaining	O
strips	O
___	O
days	O
after	O
surgery.	O
Followup	O
Instructions:	O
___	O

